Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR2 | Q8NFJ6 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20936154 | 1.00 | PROKR2 (0.67) | PROKR2KDM4EPDCD1CD274ALDH1A1 | |
| SCHEMBL565483 | 0.96 | PROKR2 (0.66) | PROKR2KDM4EPDCD1CD274ALDH1A1 | |
| SCHEMBL20936058 | 0.96 | PROKR2 (0.66) | PROKR2KDM4EPDCD1CD274ALDH1A1 | |
| SCHEMBL565419 | 0.93 | PROKR2 (0.72) | PROKR2KDM4EPDCD1CD274ALDH1A1 | |
| SCHEMBL10106694 | 0.93 | PROKR2 (0.67) | PROKR2KDM4EPDCD1CD274ALDH1A1 | |
| SCHEMBL10107258 | 0.93 | PROKR2 (0.67) | PROKR2KDM4EPDCD1CD274ALDH1A1 | |
| SCHEMBL565417 | 0.93 | PROKR2 (0.67) | PROKR2KDM4EPDCD1CD274ALDH1A1 | |
| SCHEMBL565160 | 0.93 | PROKR2 (0.67) | PROKR2KDM4EPDCD1CD274ALDH1A1 | |
| SCHEMBL10107560 | 0.92 | PROKR2 (0.66) | PROKR2KDM4EPDCD1CD274ALDH1A1 | |
| SCHEMBL565371 | 0.92 | PROKR2 (0.66) | PROKR2KDM4EPDCD1CD274ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10780095-B2 | Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-22 | — | — | US | disclosed |
| US-10780095-B2 | Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190117668-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS OF CIRCADIAN AND DIURNAL RHYTHMS USING PROKINETICIN 2 AGONISTS AND ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-25 | — | — | US | disclosed |
| US-20190117668-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS OF CIRCADIAN AND DIURNAL RHYTHMS USING PROKINETICIN 2 AGONISTS AND ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117668-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS OF CIRCADIAN AND DIURNAL RHYTHMS USING PROKINETICIN 2 AGONISTS AND ANTAGONISTS | PER2, PROKR2, PROKR1 | PROKR2 2/4885KDM4E 3164/4885PDCD1 4759/4885 |
| US-10780095-B2 | Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists | PER2, PROKR2, PROKR1 | PROKR2 2/4885KDM4E 3164/4885PDCD1 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.